Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | China Petroleum and Chemical Corp | 1,807 |
| 2 | BASF SE | 1,026 |
| 3 | Sinopec Research Institute of Petroleum Processing | 917 |
| 4 | Mitsui Chemicals Inc | 646 |
| 5 | 3M Innovative Properties Co | 632 |
| 6 | Mitsubishi Chemical Corp | 538 |
| 7 | Fujifilm Holdings Corp | 528 |
| 8 | Sumitomo Chemical Co Ltd | 519 |
| 9 | Toyobo Co Ltd | 500 |
| 10 | Dalian Institute of Chemical Physics | 406 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | Y02E | Climate change mitigation: energy | 13,343 |
| 2 | B01J | Chemical/physical processes (e.g. catalysts) | 10,035 |
| 3 | H01M | Batteries and accumulators | 8,483 |
| 4 | C07C | Acyclic and carbocyclic compounds | 7,911 |
| 5 | A61K | Medicinal preparations | 7,824 |
| 6 | A61P | Therapeutic activity (drug indications) | 7,735 |
| 7 | Y02P | Climate change mitigation: production | 7,080 |
| 8 | C12N | Microorganisms, enzymes | 7,048 |
| 9 | C07D | Heterocyclic compounds | 6,785 |
| 10 | C01P | Inorganic compound parameters | 4,807 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Preparation method of PAN/CoCl2/CNTs composite nano fibers and application of PAN/CoCl2/CNTs composite nano fibers to NaBH4 hydrogen production | 2015 | LIAOMING PETROCHEMICAL UNIV. | 9 |
| Use of CoCl#-[2] in preparation of drug for treating leukemia | 2004 | SHANGHAI NO. 2 MEDICAL UNIV. | 3 |
| Use of CoCl#-[2] in preparation of drug for treating leukemia | 2006 | SHANGHAI NO. 2 MEDICAL UNIV. | 1 |
| Process for production of CoCl2 solution from cobaltic oxide-hydrate | 1983 | Vale Canada Ltd | 1 |
| Process of separating substantially pure ferrous chloride from a mixture of fecl2 and cocl2 | 1954 | REPUBLIC STEEL CORPORATION | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Cancer, Hypoxia, and Metabolism | 23 |
| 2 | Adipose Tissue and Metabolism | 2 |
| 3 | Heme Oxygenase-1 and Carbon Monoxide | 2 |
| 4 | Neuroscience of respiration and sleep | 2 |
| 5 | Pancreatic function and diabetes | 2 |
| 6 | Retinal Diseases and Treatments | 2 |
| 7 | Trace Elements in Health | 2 |
| 8 | Amino Acid Enzymes and Metabolism | 1 |
| 9 | Anesthesia and Neurotoxicity Research | 1 |
| 10 | Angiogenesis and VEGF in Cancer | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Fernando Morgan de Aguiar Corrêa | Universidade de São Paulo | 17 |
| 2 | Ademola Adetokunbo Oyagbemi | University of Ibadan | 9 |
| 3 | Anju Bansal | Defence Institute of Physiology and Allied Sciences | 8 |
| 4 | Aiping Lan | Sun Yat-sen University | 7 |
| 5 | Alexey A. Tinkov | Sechenov University | 6 |
| 6 | América A. Scopinho | Universidade de São Paulo | 6 |
| 7 | Anatoly V. Skalny | Sechenov University | 6 |
| 8 | Carlos C. Crestani | Universidade de São Paulo | 6 |
| 9 | Leonardo B.M. Resstel | Universidade de São Paulo | 6 |
| 10 | Li Li | Shihezi University | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Purification and Characterization of Hypoxia-inducible Factor 1 | 1995 | 2078 | Epigenetics and DNA Methylation |
| Reactive Oxygen Species Generated at Mitochondrial Complex III Stabilize Hypoxia-inducible Factor-1α during Hypoxia | 2000 | 1965 | Cancer, Hypoxia, and Metabolism |
| Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin | 2002 | 1179 | Cancer, Hypoxia, and Metabolism |
| Metal-triggered Structural Transformations, Aggregation, and Fibrillation of Human α-Synuclein | 2001 | 1100 | Parkinson's Disease Mechanisms and Treatments |
| Autocrine VEGF Signaling Is Required for Vascular Homeostasis | 2007 | 1048 | Angiogenesis and VEGF in Cancer |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition and weight of cobalt chloride?
Which organizations hold the most patents for cobalt chloride applications?
What are the primary research topics associated with cobalt chloride in academic literature?
What patent classifications are most relevant to cobalt chloride technology?
How has patent activity for cobalt chloride changed in recent years?